Description
Early use of telmisartan/HCTZ dual combinations may be a suitable approach for difficult-to-treat patients with moderate to severe hypertension. The pooled data indicate that antihypertensive treatment using combinations of telmisartan/HCTZ, particularly high-dose T80/H25, is effective and well tolerated in patients older than 65 years as well as in younger patients. This finding, combined with the pharmacokinetic advantages of telmisartan, suggests that telmisartan/HCTZ may be a beneficial combination for older hypertensive patients who may have added CV risk factors and who are generally difficult to treat to goal.
